Holen Sie sich die Stockscreener-App
70.34
1.99%
1.37
Schlusskurs vom Vortag:
$68.97
Offen:
$68.97
24-Stunden-Volumen:
2.19M
Relative Volume:
1.02
Marktkapitalisierung:
$8.27B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
23.29
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+0.44%
1M Leistung:
+5.17%
6M Leistung:
+30.43%
1J Leistung:
+53.92%
1-Tages-Spanne:
$68.09
$70.76
1-Wochen-Bereich:
$68.09
$72.71
52-Wochen-Spanne:
$46.21
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
70.34 | 8.11B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Acquires Drug Delivery Company Elektrofi - CHEManager
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects - Yahoo Finance
Is Halozyme Therapeutics Inc. (RV7) stock nearing a technical breakoutJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zone - newser.com
What Recent Analyst Upgrades and Partnerships Mean for Halozyme’s Evolving Story and Valuation - Yahoo Finance
Does the Latest Halozyme Partnership Signal Further Upside for the Stock in 2025? - Yahoo Finance
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
How strong dollar benefits Halozyme Therapeutics Inc. (RV7) stock2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Halozyme Therapeutics expands portfolio with Elektrofi acquisition - Traders Union
How Halozyme Therapeutics Inc. (RV7) stock performs in volatility spikesWeekly Trade Review & Detailed Earnings Play Alerts - newser.com
[S-8] HALOZYME THERAPEUTICS, INC. Employee Benefit Plan Registration | HALO SEC FilingForm S-8 - Stock Titan
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - Nasdaq
What drives Halozyme Therapeutics Inc stock priceVolume Profile Analysis & High Return Capital Gain - earlytimes.in
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HAL - GuruFocus
Halozyme Therapeutics Acquires Elektrofi for $750M - Contract Pharma
Halozyme Therapeutics Completes Elektrofi Acquisition - MarketScreener
Halozyme completes acquisition of Elektrofi for $750 million By Investing.com - Investing.com Nigeria
Halozyme completes acquisition of Elektrofi for $750 million - Investing.com
Halozyme completes acquisition of Elektrofi, expanding breadth of offerings in drug delivery - MarketScreener
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery - PR Newswire
Halozyme Therapeutics, Inc. completed the acquisition of Elektrofi, Inc. - MarketScreener
Merus and Halozyme partner on subcutaneous cancer drug delivery By Investing.com - Investing.com Nigeria
Halozyme stock price target raised to $56 from $54 at Goldman Sachs - Investing.com
Merus N.V. and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - MarketScreener
Merus, Halozyme Partner to Develop Subcutaneous Formulation of Petosemtamab - Contract Pharma
Merus and Halozyme link up on petosemtamab development - The Pharma Letter
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics - Nasdaq
Halozyme (HALO) Enters Collaboration Agreement with Merus - GuruFocus
Merus and Halozyme enter global collaboration and license agreement to develop subcutaneous formulation of Petosemtamab - MarketScreener
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - Merus
Merus and Halozyme partner on subcutaneous cancer drug delivery - Investing.com
Merus (MRUS) and Halozyme (HALO) license ENHANZE to develop subcutaneous petosemtamab - Stock Titan
Will Halozyme Therapeutics Inc. price bounce be sustainablePortfolio Performance Summary & Community Driven Trade Alerts - newser.com
Where is Halozyme Therapeutics (HALO) Headed According to Analysts? - MSN
Strategies to average down on Halozyme Therapeutics Inc.Weekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-11-16 05:36:24 - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastSector Performance Drivers & Fast Growing Trading Ideas - earlytimes.in
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):